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Abstract
Background: To determine prevalence and incidence of bacterial vaginosis (BV) and risk factors in young sexually-active
Australian women.
Methods: 1093 women aged 16–25 years were recruited from primary-care clinics. Participants completed 3-monthly
questionnaires and self-collected vaginal smears 6-monthly for 12-months. The primary endpoint was a Nugent Score = 7–
10 (BV) and the secondary endpoint was a NS = 4–10 (abnormal flora [AF]). BV and AF prevalence estimates and 95%
confidence intervals (95%CI) were derived, and adjusted odds ratios (AOR) calculated to explore epidemiological
associations with prevalent BV and AF. Proportional-hazards regression models were used to examine factors associated
with incident BV and AF.
Results: At baseline 129 women had BV [11.8% (95%CI: 9.4–14.2)] and 188 AF (17.2%; 15.1–19.5). Prevalent BV was
associated with having a recent female partner [AOR= 2.1; 1.0–4.4] and lack of tertiary-education [AOR= 1.9; 1.2–3.0]; use of
an oestrogen-containing contraceptive (OCC) was associated with reduced risk [AOR= 0.6; 0.4–0.9]. Prevalent AF was
associated with the same factors, and additionally with .5 male partners (MSP) in 12-months [AOR= 1.8; 1.2–2.5)], and
detection of C.trachomatis or M.genitalium [AOR= 2.1; 1.0–4.5]. There were 82 cases of incident BV (9.4%;7.7–11.7/100
person-years) and 129 with incident AF (14.8%; 12.5–17.6/100 person-years). Incident BV and AF were associated with a new
MSP [adjusted rate ratio (ARR) = 1.5; 1.1–2.2 and ARR= 1.5; 1.1–2.0], respectively. OCC-use was associated with reduced risk
of incident AF [ARR= 0.7; 0.5–1.0].
Conclusion: This paper presents BV and AF prevalence and incidence estimates from a large prospective cohort of young
Australian women predominantly recruited from primary-care clinics. These data support the concept that sexual activity is
strongly associated with the development of BV and AF and that use of an OCC is associated with reduced risk.
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Introduction
Bacterial vaginosis (BV) is the most common cause of abnormal
vaginal discharge in women of reproductive age. However,
internationally, most BV prevalence and incidence data are
derived from testing women attending sexual/reproductive
services, rather than from community-based screening studies.
The widely cited 2001-4 U.S. National Health and Nutrition
Survey (NHANES) showed 29% of 14–49 year old women had
BV, with higher prevalence among African-American (51.6%)
compared to Hispanic (32.1%) and Caucasian (23.2%) women [1].
While a study of asymptomatic women attending general practices
in the United Kingdom, and a study of Australian university
students, reported notably lower prevalence estimates of 9% and
5% respectively [2,3]. Some of the highest community-based
estimates have been reported from rural sub-Saharan Africa, with
a systematic review of women attending antenatal facilities finding
pooled BV prevalence estimates of 51% in East/Southern Africa
and 38% in West/Central Africa [4].
BV incidence studies have generally been conducted in high
prevalence populations, with a high proportion of participants
from STI clinics or from disadvantaged backgrounds. These
studies are likely to provide higher BV incidence estimates
compared with community-based samples and have tended to
report rates in excess of 20/100 woman-years [5,6,7,8,9,10,11,12].
In contrast, a prospective study of 17–21 year old Australian
university students reported a low incidence rate of 2.2/100
woman-years in sexually-active participants, and no incident BV
in sexually-inactive women [13].
While the aetiology of BV and whether it is sexually transmitted
remains unclear, epidemiological studies show a consistent
association between BV and sexual activity. Some of the strongest
evidence comes from a meta-analysis of 43 studies which found
prevalent and incident BV were associated with new or multiple
male partnerships, report of female partners and inconsistent
condom use [14]. Observational studies have, however, also
reported associations between increased risk of BV and non-sexual
behavioural practices such as smoking [15] and vaginal douching/
cleaning practices [16], and a number of cross-sectional and
longitudinal studies have shown a reduced risk of BV in women
using hormonal contraceptives [6,17,18,19,20,21]. Current anti-
biotic regimens for BV have limited effectiveness with up to 60%
of women experiencing recurrence within 12 months [17].
Improving our understanding of how behavioural factors are
associated with the development and recurrence of BV is integral
to developing more effective approaches for the prevention and
treatment of BV.
We present BV prevalence and incidence estimates, derived
using the Nugent method, and examine the associated risk factors
for the development of BV and abnormal flora (AF), in a large
cohort study of young sexually-active women predominantly
recruited from primary-care clinics. These are the first commu-
nity-based estimates for the Australian population.
Methods
Recruitment, Clinical and Laboratory Methods
Women aged 16 to 25 years attending 29 primary-care services
(general practice/family planning/sexual health services) in three
Australian states, for any reason, were invited to participate in a
cohort study to determine C.trachomatis incidence and re-infection
rates (detailed methods described elsewhere) [22]. Participants
were also invited to enroll in a sub-study to determine the
prevalence and incidence of BV and Mycoplasma genitalium. Women
were eligible if they were sexually-active, aged 16–25 years, not
pregnant and contactable by post. Research assistants approached
consecutive eligible women at clinic sites and obtained written
informed-consent. Participants completed 3-monthly question-
naires on demographic, sexual and behavioural data, recent
antibiotic and contraceptive use, and genital symptoms. They self-
collected a vaginal swab and smeared the sample onto a glass slide
in clinic at baseline, and then at home at 6 and 12 months.
Samples and questionnaires were returned by post.
BV was defined as a Nugent score (NS) of 7–10, intermediate
flora as a NS= 4–6, and normal flora as a NS=0–3 [23].
Abnormal flora (AF) was defined as a NS=4–10. All slides were
scored by an experienced microbiologist. An independent senior
microbiologist reread all NS 6 and 7 slides, had 50 problematic
slides referred to her for a second opinion, and additionally
randomly audited 10% of slides in each Nugent category.
Concordance in the random audit was 92%; 9/112 slides were
found to have a minor discrepancy defined as a difference of$2 in
Nugent score that did not result in misclassification of BV, or
normal versus intermediate flora. Use of self-collected samples for
BV diagnosis has been shown to be comparable to clinician-
collected samples [24]. Women with symptomatic BV were treated
with metronidazole 400 mg orally twice daily or 2%-clindamycin
cream vaginally for 7 nights.
Participants were tested for C.trachomatis and M.genitalium at
baseline and during follow-up by PCR using the Cobas-TaqMan
CT-assay (Roche Applied Science) and a PCR-assay targeting the
517 bp region of the 16S rRNA gene of M.genitalium, respectively
[25]. Detailed laboratory methodology and results have been
described elsewhere [22,26].
Statistical Methods
Data were analysed using STATA 12.0 (StataCorp LP,College
Station,USA). Assuming a design effect of 2 to take account of
within-clinic correlation, a sample size of 1000 women was
sufficient to generate 95% confidence intervals (CIs) of 7.2–12.8/
100 person-years if the estimated incidence rate was 10/100
person-years.
BV and AF prevalence estimates and 95% CIs were calculated
adjusting for within-clinic correlation. Adjusted odds ratios (AOR)
and robust standard errors were calculated to explore epidemio-
logical associations of variables with the primary outcome,
prevalent BV (NS 7–10 versus NS 0–6), and secondary outcome,
AF (NS 0–3 versus NS 4–10).
Women with a NS,7 at baseline were included in the cohort
analysis. Incident BV was defined as the first occurrence of a
NS= 7–10 in a participant with a previous NS,7; this led to a
participant being censored from the incidence analysis. The
association between risk factors and incident BV was investigated
using a discrete-time version of the proportional-hazards regres-
sion model [27]. Variables were included in the model on the basis
of the likelihood ratio test, or if they had been associated with BV
in previous studies. Follow-up concluded 18 months after
enrolment. The same statistical methods were applied to
examination associations with incident AF.
Written informed consent was obtained from all participants.
All eligible women were assessed for competency by research staff
prior to being invited into the study. The research staff worked
closely with the clinical staff to ensure only competent women
were approached. All ethics committees approved the inclusion of
participants over the age of 16 without parental or guardian
consent. Ethics approval to conduct this study was obtained from
ten Human Research Ethics Committees throughout Australia
including: The Australian Capital Territory (ACT) Health Human
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Research Ethics Committee, ACT; The Alfred Health Ethics
Committee, Melbourne; The University of Ballarat Ethics
Committee, Ballarat, Victoria; Family Planning Victoria Human
Research Ethics Committee, Victoria; The North Coast Area
Health Service, Human Research Ethics Committee, New South
Wales (NSW); The South Eastern Sydney Area Health Service,
Human Research Ethics Committee - Northern Area, NSW; The
University of Melbourne, Human Research Ethics Committee,
Victoria; The University of Newcastle Human Research Ethics
Committee, NSW; The University of NSW Human Research
Ethics Committee, NSW; Family Planning NSW Research Ethics
Committee, NSW [22,26].
Results
Demographic and Behavioural Characteristics of the
Study Population
Overall, 1116 women aged 16 to 25 years were recruited from
29 clinic-sites across Australia, with an overall response rate of
66% [22,26]. A total of 1110 women (99.5%) agreed to participate
in the BV sub-study. Of these 1093 (98.5%) provided a readable
baseline slide and behavioural data, and were included in
prevalence analyses. Nine hundred and sixty-four (88.2%) women
with a baseline NS,7 continued in the cohort study, provided $1
slides and behavioural data, and contributed 871.20 person years
of follow-up to incidence analyses.
Participants had a median age of 21 years, and were
predominantly recruited from general practice (66%), Table 1.
The majority (88%) were Australian-born, 24 (2%) were Aborig-
inal or Torres Strait Islander, 471 (44%) had completed tertiary
studies, and 408 (38%) were employed. At baseline 638 (58%)
women were using hormone-based contraception: 567 (89%) used
the combined oral contraceptive pill (COCP), 5 (1%) an intra-
vaginal ring, and 66 (10%) a progesterone implant or depot-
injection. Seven women had an intra-uterine device; whether it
was a levo-norgesterel device was unknown. In the prior year, one
third of participants had $3 male sexual partners (MSP) and 103
(9%) $1 female partners (FSP).
Baseline Clinical and Laboratory Characteristics of the
Study Population
At baseline, 129 women had a NS of 7–10 [11.8% (95%CI: 9.4–
14.2)], Table 1. Fifty-nine women had intermediate flora (5.4%;
4.0–6.8), and 905 had normal flora (82.8%; 80.1–85.5). The
prevalence of AF was 17.2% (15.1–19.5). At recruitment, 246
(23%) women reported an abnormal vaginal discharge and 184
(17%) an abnormal odour. Twelve women had concurrent BV
and C.trachomatis[1.1%; 0.5–1.7)], and 4 concurrent BV and
M.genitalium[0.4%; 0.0–0.7)], Figure 1.
Factors Associated with Prevalent BV and AF
By univariate analysis, women with prevalent BV were more
likely to be recruited from sexual health/family planning services
(OR=1.7; 1.1–2.5), to have no tertiary education (OR=2.2; 1.4–
3.5), to be born overseas (OR=1.6; 1.0–2.7), and in the prior year
to report a FSP (OR=2.7; 1.6–4.7) and $5 new MSPs (OR=2.2;
1.2–3.9), Table 1. Current use of an oestrogen-containing
contraception (OCC, defined as COCP or ring) was associated
with a lower prevalence of BV (OR=0.6; 0.4–0.8), while use of
any hormone-based method was not (OR=0.8; 0.5–1.2). Co-
detection of C.trachomatis or M.genitalium had a borderline associ-
ation with BV (OR=2.0; 0.9–4.4). Women with prevalent BV
were more likely to report an abnormal vaginal discharge
(OR=1.6; 1.1–2.4) or odour (OR=3.0; 2.2–4.1).
By multivariate logistic regression analysis, women with
prevalent BV were more likely to have had a FSP in the prior
year (AOR=2.1; 1.0–4.4), and no tertiary education (AOR=1.9;
1.2–3.0). OCC-use was associated with decreased odds of BV
(AOR=0.6; 0.4–0.9), and there was a borderline association with
co-detection of C.trachomatis or M.genitalium [AOR=2.0; 0.9–4.6),
Table 1. Clinical symptoms were not included in multivariate
analyses.
The findings for prevalent AF did not greatly differ from BV.
Women with prevalent AF were more likely in the last year to have
had a FSP [AOR=1.9; 1.0–3.6)], and $5 new MSPs (AOR=1.8;
1.2–2.5), to be co-infected with C.trachomatis or M.genitalium
(AOR=2.1; 1.0–4.5) and to have no tertiary education
(AOR=1.6; 1.2–2.3); OCC-use decreased the odds of
AF(AOR=0.7; 0.5–1.0).
Incidence and Risk Factors Associated with BV and AF
There were 82 cases of incident BV [9.4 (95% CI: 7.7–11.7)/
100 person-years], and incidence was stable during follow-up at
9.3 (95% CI: 5.8–14.9)/100 person years over the first 6 months
and 9.4 (95% CI:7.4–12.0)/100 person years over the last 6
months.
By univariate analysis, incident BV was associated with being
employed (RR=1.4; 1.0–2.0), and having a new MSP during
follow-up (RR=1.6; 1.2–2.3), Table 2. OCC-use in the 3-months
prior to testing was associated with lower rates of incident BV
(RR=0.7; 0.5–1.0); use of any hormonal contraceptive was not
(RR=0.8; 0.5–1.2). Women with incident BV were more likely to
report genital symptoms in the interval prior to testing including
an abnormal vaginal discharge (RR=1.9; 1.3–2.7), odour
(RR=2.9; 2.0–4.1), or abdominal pain (RR=1.5; 1.1–2.1). By
multivariate analysis, having a new MSP during follow-up was
associated with incident BV (ARR=1.5; 1.1–2.2); there was a
borderline reduction in the risk of incident BV with OCC-use
(ARR=0.7; 0.5–1.1), Table 2.
There were 129 cases of incident AF during the study [14.8
(95% CI: 12.5–17.6)/100 person-years]. By multivariate analysis,
having a new MSP during the study was associated with incident
AF (ARR=1.5; 1.1–2.0) and OCC-use was associated with a
reduced risk of incident AF (ARR=0.7; 0.5–1.0).
Discussion
This study presents findings on the prevalence and incidence of
BV and AF among a large community-based cohort of Australian
women. In this young cohort we found that exposure to a new
male partner was associated with increased risk of incident BV and
AF, while use of an OCC was associated with a reduced risk. The
young age and low BV prevalence in participants, together with
the stable BV incidence throughout the study, all facilitated the
study of the association between recent sexual and contraceptive
behaviours and the development of incident BV. These are the
first data to give an estimation of the prevalence (12%) and
incidence (9.4/100 person years) of BV in young Australian
women in the community. Our findings indicate that sexual
exposure to new partners is influential in the development of BV
and AF, and that OCC appears to be associated with a reduced
risk.
The prevalence and incidence of BV in this large cohort of
young Australian women is significantly lower than that reported
from the NHANES data [1], and the majority of prospective
studies in heterosexual women [5,6,7,8,9,10,11,12]. This is likely
to be due to the young age of our participants and the fact that the
majority were recruited from primary-care compared with those in
Bacterial Vaginosis in Australian Women
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Table 1. Demographic and behavioural associations with prevalent bacterial vaginosis by univariate and multivariate analysis
(n = 1093).
Variable N (%) Prevalence (95%CI) Unadjusted ORa (95% CI) Adjusted ORa,b (95% CI)
Age
16–20 455 (41.6) 11.4 (9.0, 13.9) 1.0
21–25 638 (58.4) 12.3 (9.3, 15.3) 1.1 (0.8, 1.5)
Recruitment site
General practice 726 (66.4) 9.9 (7.7, 12.1) 1.0 1.0
Sexual health/family planning 367 (33.6) 15.5 (11.8, 19.3) 1.7 (1.1, 2.5) 1.2 (0.8, 1.7)
Country of birth
Australian born 916 (88.4) 10.5 (8.5, 12.5) 1.0
Not Australian born 120 (11.6) 15.8 (9.2, 22.4) 1.6 (1.0, 2.7)
Aboriginal/Torres Strait Islanderc
No 1038 (97.7) 6.9 (0.0, 26.8) 1.0
Yes 24 (2.3) 11.3 (9.3, 13.2) 1.1 (0.3, 3.7)
Highest education status
Completed tertiary studies 593 (55.7) 7.2 (4.9, 9.6) 1.0 1.0
Completed secondary studies 471 (44.3) 14.5 (11.7, 17.3) 2.2 (1.4, 3.5) 1.9 (1.2, 3.0)
Employment status
Unemployed 408 (38.3) 12.0 (8.8, 15.2) 1.0
Employed 656 (61.7) 11.0 (8.6, 13.4) 0.9 (0.7, 1.3)
Number of male sex partners in prior 12
months
0–2 704 (67.2) 9.4 (6.9, 11.9) 1.0 1.0
3–4 207 (16.4) 12.6 (8.0, 17.1) 1.4 (0.8, 2.3) 1.3 (0.7, 2.2)
5+ 136 (7.2) 18.4 (10.0, 26.7) 2.2 (1.2, 3.9), p,0.01d 1.6 (0.8, 3.1), p = 0.12d
Any female sex partners in prior 12 months
No 990 (90.6) 10.5 (8.4, 12.6) 1.0 1.0
Yes 103 (9.4) 24.3 (13.8, 34.7) 2.7 (1.6, 4.7) 2.1 (1.0, 4.4)
Current use of oestrogen-containing
contraception
No 497 (46.5) 14.5 (11.4, 17.6) 1.0 1.0
Yes 572 (53.5) 8.7 (6.3, 11.2) 0.6 (0.4, 0.8) 0.6 (0.4, 0.9)
Coinfection with C.trachomatis or
M.genitalium
No 1014 (92.8) 1.1 (8.6, 13.7) 1.0 1.0
Yes 79 (7.2) 20.2 (8.7, 31.8) 2.0 (0.9, 4.4) 2.0 (0.9, 4.6)
Self-reported history of BV
No 1007 (94.7) 11.1 (8.8, 13.5) 1.0
Yes 56 (5.3) 16.1 (6.7, 25.4) 1.5 (0.8, 3.1)
Antibiotic use in last 2 months
No 785 (73.5) 12.1 (9.3, 14.8) 1.0
Yes 285 (26.5) 9.2 (0.1, 12.5) 0.7 (0.5, 1.1)
Abnormal vaginal discharge*
No 822 (77.0) 10.1 (7.8, 12.2) 1.0
Yes 246 (23.0) 15.4 (10.7, 20.2) 1.6 (1.1, 2.4)
Abnormal vaginal odour*
No 884 (82.8) 8.9 (7.0, 10.9) 1.0
Yes 184 (17.2) 22.8 (16.9, 28.8) 3.0 (2.2, 4.1)
Baseline Nugent score
0–3 905 (82.8) 82.8 (80.1, 85.5)
4–6 59 (5.4) 5.4 (4.0, 6.8)
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published studies. Our prevalence data are more in keeping with a
UK study of women attending general practices for cervical
cytology (9%) [2], but notably higher than that found in 17–21
year old Australian university students (5%) [3]. Our data supports
the previously reported association between BV and lower levels of
education, which is likely to be more broadly reflective of socio-
economic and health inequity, and greater levels of sexual risk
behaviour [1,28].
Incident BV and AF, in this young predominantly heterosexual
cohort, were associated with report of a new male partner. A
number of investigators have reported an association between the
development of BV and exposure to a new male partner [5,7,9]. In
a study of women recruited from an STI service, sex with a new
partner was the only behaviour associated with incident BV [7]. In
a cohort of female sex workers in West Africa, Nagot reported
having $3 male sex partners in the prior week was associated with
incident BV [9]. Using cohort and case cross-over analytical
methods to reduce unmeasured confounding, Gallo found the only
consistent association with incident BV in high-risk women was
detection of spermatozoa on Gram stain [29]. In our cohort
increased numbers of male partners in the year prior to enrolment
was also associated with increased odds of prevalent AF but not
BV. It is interesting to note the association reported in the meta-
analysis between new or multiple male partnerships and prevalent
and incident BV was of similar magnitude to that found in the
current cohort (RR=1.6; 95% CI: 1-5-1.8) [14].
It was not only exposure to male partners that conferred an
increased risk of BV in this community cohort, but report of
female partners in the prior year doubled the odds of prevalent BV
and AF. The association between increased BV risk and female
partnerships is well known but poorly understood. A higher
prevalence of BV is consistently reported in lesbians compared to
heterosexual women within the same communities, and high levels
of concordance of vaginal flora has been reported between
monogamous female partners [30,31,32]. Again the magnitude of
the effect observed in our cohort was strikingly similar to that
found by meta-analysis which showed report of any female
partner(s) doubled the odds of BV (RR=2.0; 95% CI 1.7–2.3)
[14]. While these data are compelling, the fundamental question
as to whether sexual activity with male or female partners
contributes to the development of BV through transmission of BV
associated-bacteria, or instead is impacting adversely on vaginal
colonization with protective Lactobacillus species, remains unan-
swered. The association between BV and increased detection of
STIs, which has been reported in a number of studies [5,33,34]
provides further support for the strong relationship between BV
and sexual activity. However, whether BV increases susceptibility
to STIs, or BV and STIs are co-infections that result from shared
risk factors is unknown.
Use of an OCC in this cohort was associated with a reduced risk
of prevalent BV and AF, and incident AF, after adjusting for
confounding factors including numbers of sexual partners. This
predominantly reflected COCP use in this cohort, and when use of
any hormonal contraceptive, which included progesterone-only
methods, was examined there was no significant association. This
association has been evident in a number of published studies.
Hormonal contraceptives, mainly combined methods, have been
reported to be protective against prevalent [18,19,20], incident
[6,35] and recurrent [17,19,21] BV. While there are a number of
confounding factors that may explain this association it is
consistently evident in the literature, and many analyses including
our own, have adjusted for known confounders such as numbers of
sexual partners and educational level. There are also biologically
plausible explanations for this apparent association. It has been
hypothesized that oestrogen increases the glycogen-content of
epithelial cells, a substrate for Lactobacillus species to generate lactic
acid, which appears to be a potent inhibitor of BV-associated
bacteria [36]. It is possible that contraceptive use influences the
vaginal immune response, with Cherpes reporting an association
between hormonal contraceptive use and altered vaginal immu-
nity in BV [37]. Clearly further studies are need to determine if
and how OCC may provide protection against BV or whether the
observed association is due to unmeasured confounding.
There were a number of limitations to our study. Participants
were more likely to be Australian-born, better educated, and more
sexually-active than the background Australian population of this
age [22,38]. As a consequence, our study may not be represen-
tative of all Australian 16–25 year old women. Two thirds of
recruits were derived from general practice and the remainder
from sexual health/family planning services. BV prevalence was
slightly higher in recruits from family planning/sexual health
services compared to general practices, however, the BV incidence
Figure 1. Cases of bacterial vaginosis, Chlamydia trachomatis
and Mycoplasma genitalium at recruitment and co-infections.
doi:10.1371/journal.pone.0057688.g001
Table 1. Cont.
Variable N (%) Prevalence (95%CI) Unadjusted ORa (95% CI) Adjusted ORa,b (95% CI)
7–10 129 (11.8) 11.8 (9.4, 14.2)
a = odds ratio; b =multivariate analysis including: recent female sex partner, current use of oestrogen containing contraception, numbers of male sex partners,
recruitment site (sexual health/family planning clinic or general practice clinic), education level achieved, tested positive for chlamydia at baseline; c = Identify as
Aboriginal and/or Torres Strait Islander Origin; d = test for trend; * self-reported and note clinical symptoms are not included in any multivariate analyses.
doi:10.1371/journal.pone.0057688.t001
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did not differ between these sites, and care was taken to adjust all
analyses for clinic type. The inclusion of sexual health/family
planning services in this cohort may have some impact on the
generalizability of prevalence and incidence estimates, however, it
is less likely to effect the measures of association (relative risks).
Overall, 80–90% of young Australian women visit a general
practice clinic each year [39], so this study population should
provide a reasonable sample of young women in the community in
this age group. Another important limitation is that the precision
of our estimates of BV incidence reflect the availability of event
data, which was constrained by six-monthly sample collection.
Studies employing Gram stain analysis and more sensitive
molecular methods, such as quantitative PCR and pyrosequenc-
ing, have shown that the vaginal microbiota can be highly
dynamic. Dramatic changes in lactobacillus and BV-associated
bacterial species, and rapid fluctuation in Nugent scores can occur
in some individuals over a menstrual cycle, although longitudinal
studies have also shown that vaginal bacterial communities can be
more stable in some women than others [40,41,42,43,44,45].
These studies indicate that factors such as menstruation and sexual
behaviours may influence the stability of the vaginal microbiota in
women, however the clinical significance of these fluctuations is
Table 2. Demographic and behavioural associations with incident bacterial vaginosis by univariate and multivariate analysis.
Characteristic
Rate per 100,000 woman
years (95%CI) Unadjusted RRa (95% CI) Adjusted RRb (95% CI)
Age
16 to 20 9.8 (7.4, 12.8) 1.0
21 to 25 8.9 (6.3, 12.6) 0.8 (0.6, 1.2)
Recruitment site
General practice 8.8 (6.7, 11.4) 1.0 1.0
Sexual health/family planning 10.9 (7.6, 15.6) 1.2 (0.9, 1.8) 1.2 (0.8, 1.8)
Country of birth
Australian born 8.6 (6.8, 11.1) 1.0
Not Australian born 11.3 (6.1, 21.0) 1.5 (0.9, 2.6)
Aboriginal/Torres Strait Islanderc
No 9.1 (7.2, 11.3) 1.0
Yes 9.2 (2.3, 36.6) 0.5 (0.1, 2.0)
Education status
Completed secondary studies 10.1 (7.4, 13.7) 1.0
Completed tertiary studies 8.1 (5.9, 11.2) 1.1 (0.8, 1.6)
Employment status
Not currently employed 8.4 (5.8, 12.2) 1.0 1.0
Employed 9.5 (7.2, 12.5) 1.4 (1.0, 2.0) 1.4 (0.9, 2.0)
Recentd new male sexual partner
No 7.9 (6.0, 10.4) 1.0 1.0
Yes 14.1 (9.9, 20.2) 1.6 (1.2, 2.3) 1.5 (1.1, 2.2)
Recentd female sex partner
No 9.1 (7.3, 11.5) 1.0
Yes 13.1 (6.5, 26.1) 1.5 (0.8, 2.5)
Use of oestrogen containing contraception
No 11.3 (8.4, 15.2) 1.0 1.0
Yes 8.0 (5.8, 10.9) 0.7 (0.5, 1.0) 0.7 (0.5, 1.1)
Recentd Mycoplasma genitalium infection
No 10.1 (8.1, 12.4) 1.0
Yes 6.9 (0.2, 33.9) 0.5 (0.1, 3.4)
Recentd Chlamydia trachomatis infection
No 9.2 (7.4, 11.5) 1.0
Yes 17.0 (6.4, 45.3) 1.5 (0.7, 3.4)
Antibiotic use in the last 2 months
No 8.3 (6.4, 10.8) 1.0
Yes 13.5 (9.2, 19.8) 1.0 (0.7, 1.5)
a = rate ratio; b =multivariate analysis including: recent new male sex partner, current use of oestrogen containing contraception, currently employed, recruitment site
(sexual health/family planning clinic or general practice clinic); c = Aboriginal and/or Torres Strait Islander origin. d = recent refers to within the 3 months prior to testing.
doi:10.1371/journal.pone.0057688.t002
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not currently known. Importantly, the broad sampling interval in
this study means cases of BV could have been missed, which may
have lead to an under-estimate of the incidence rate. Of note,
there was a significant association between self-report of abnormal
vaginal discharge and/or odour and diagnosis of incident BV by
the Nugent method, indicating that cases of incident infection that
were detected were more likely to represent clinically significant
BV.
Overall the strengths of this study include the diverse range of
geographical location and socio-economic status from which
participants were recruited, the high recruitment and retention
rates, and inclusion of a high proportion of under 21 year old
women (42%), a group that is difficult to engage in research. A
further strength is that the young age, the low BV prevalence, and
the stable incidence of BV throughout the study all facilitated the
study of the relationship between recent behaviours and incident
BV.
Conclusion
These are the first data to give an estimation of the prevalence
and incidence of BV in young Australian women in the
community. The consistent manner in which sexual risk factors
are identified in association with BV, in populations that differ
widely in their geographical and socioeconomic circumstances,
lends considerable weight to the concept that sexual activity with
both men and women is highly influential if not integral to the
development of BV. However, it appears likely that sexual and
contraceptive practices influence not just the development of BV
and AF but also recurrence. A recent treatment trial showed no
benefit from combining oral metronidazole with vaginal clinda-
mycin over oral metronidazole alone. BV recurrence in this cohort
was instead strongly associated with remaining with the same pre-
treatment sexual partner and inconsistent condom use, while use
of oestrogen-containing contraceptives was associated with a
reduced risk of recurrence [17,19,21]. Debate will continue as to
whether the consistent association between BV and sexual activity
is a direct result of transmission of putative agent(s) that have an
aetiological role in the development and recurrence of BV, or
whether sexual activity itself impacts adversely on vaginal
colonization with protective Lactobacillus species thereby facilitating
BV development and recurrence. We are only just beginning to
understand the diversity of the vaginal microbiota in healthy
women [41], and have yet to fully understand the effects of sexual
behaviours on it, and if and how use of hormone-based
contraceptives may influence a woman’s vaginal microbiota and
susceptibility to BV. Clearly, identifying potentially modifiable
behaviours that are associated with the development and
recurrence of BV within large cohort studies is an integral step
to the development and evaluation of targeted interventions to
improve prevention and treatment approaches for BV.
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